For example, combining a panel of two AABs (anti-leucine repeat death domain-containing protein (LRDD) and anti-forkhead box A1 (FOXA1) autoantibodies) with serum CA125 levels increased the diagnostic performance by raising the positive rate from 62.7% to 87.1% in ovarian cancer patients [105]. This evidence concerns the gene MUC16 and ovarian cancer.